EFFICACY OF ADJUVANT VERSUS NEOADJUVANT CHEMOTHERAPY IN HISPANIC/LATINO WOMEN WITH EARLY STAGE, TRIPLE NEGATIVE BREAST CANCER (TNBC)

被引：0
|
作者：
Philipovskiy, A. [1 ]
Corral, J. [1 ]
Heydariana, R. [1 ]
Gaur, S. [1 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, El Paso, TX USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2019年 / 67卷 / 02期
关键词：
D O I：
10.1136/jim-2018-000974.611
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
605
引用
收藏
页码：593 / 593
页数：1
相关论文
共 50 条
  • [1] Efficacy of Neoadjuvant Versus Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With Local or Locally Advanced Triple-negative Breast Cancer (TNBC)
    Philipovskiy, Alexander
    Corral, Javier
    Dwivedi, Kumar Alok
    Heydarian, Rosalinda
    Gaur, Sumit
    IN VIVO, 2019, 33 (04): : 1227 - 1234
  • [2] Neoadjuvant Versus Adjuvant Chemotherapy for Triple Negative Breast Cancer
    Kennedy, Carlie R.
    Gao, Feng
    Margenthaler, Julie A.
    JOURNAL OF SURGICAL RESEARCH, 2010, 163 (01) : 52 - 57
  • [3] Survival Outcome of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Early Triple Negative Breast Cancer
    Huang, Kai
    Jakub, James W.
    Gabriel, Emmanuel
    Moreno-Aspitia, Alvaro
    McLaughlin, Sarah
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S120 - S120
  • [4] Adjuvant or neoadjuvant chemotherapy in early stage triple negative breast cancer (TNBC) comparison of outcomes in both BRCA positive and BRCA negative patients.
    Clifton, Katherine
    Barrera, Angelica Gutierrez
    Ma, Junsheng
    Bassett, Roland L.
    Litton, Jennifer Keating
    Arun, Banu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
    Wein, Lironne
    Loi, Sherene
    BREAST, 2017, 34 : S27 - S30
  • [6] Adjuvant Chemotherapy in early stage Triple-Negative Breast Cancer Patients
    Pfeiler, G.
    Koenigsbergt, R.
    Natter, C.
    Jahn-Kuch, D.
    Hudec, M.
    Zeilinger, R.
    Dittrich, C.
    Singer, C.
    ONKOLOGIE, 2010, 33 : 26 - 26
  • [7] Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
    Ren, Kuojun
    Wang, Shuhan
    Ye, Tingbo
    Zhu, Zhengzhi
    Hong, Shikai
    Wang, Shengying
    Liu, Jianjun
    BMC CANCER, 2024, 24 (01)
  • [8] The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
    Abuhadra, Nour
    Chang, Chia-Chi
    Yam, Clinton
    White, Jason B.
    Ravenberg, Elizabeth
    Lim, Bora
    Ueno, Naoto T.
    Litton, Jennifer Keating
    Arun, Banu
    Damodaran, Senthil
    Murthy, Rashmi Krishna
    Ibrahim, Nuhad K.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    Tripathy, Debu
    Thompson, Alastair Mark
    Mittendorf, Elizabeth A.
    Huo, Lei
    Moulder, Stacy L.
    Jenq, Robert R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Outcomes of Hispanic/Latino women with triple negative breast cancer who achieve a complete pathologic response after neoadjuvant chemotherapy.
    Philipovskiy, Alexander
    Corral, Javier Chavez
    Heydarian, Rosalinda
    Dwivedi, Alok Kumar
    Gong Xiaoming
    Leelani, Sajid
    Gaur, Sumit
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
    Ryan, P. D.
    Tung, N. M.
    Isakoff, S. J.
    Golshan, M.
    Richardson, A.
    Corben, A. D.
    Smith, B. L.
    Gelman, R.
    Winer, E. P.
    Garber, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345